Table 1.
Characteristics of patients at diagnosis of subsequent solid cancer
| Characteristic | Total (N = 713), | Autologous (N = 217), | Allogeneic (N = 496), | P* |
|---|---|---|---|---|
| no. (%) | no. (%) | no. (%) | ||
| Median age at diagnosis of solid cancer (range), y | 55 (5-82) | 62 (10-82) | 52 (5-76) | <.001 |
| Median duration from HCT to diagnosis of solid cancer (range), y | 5.9 (1.0-25) | 4.9 (1.0-20) | 6.3 (1.0-25) | <.001 |
| Patient sex | .37 | |||
| Male | 449 (63) | 142 (65) | 307 (62) | |
| Female | 264 (37) | 75 (35) | 189 (38) | |
| Cancer type (ICD-10 code) | <.001 | |||
| Oral cavity/pharynx (C00-C14) | 117 (16) | 8 (4) | 109 (22) | |
| Esophagus (C15) | 83 (12) | 7 (3) | 76 (15) | |
| Stomach (C16) | 48 (7) | 20 (9) | 28 (6) | |
| Colon (C18-C20) | 79 (11) | 36 (17) | 43 (9) | |
| Liver (C22) | 20 (3) | 14 (6) | 6 (1) | |
| Pancreas (C25) | 25 (4) | 10 (5) | 15 (3) | |
| Lung (C33-C34) | 81 (11) | 38 (18) | 43 (9) | |
| Bone/soft tissue† (C40-C41) | 31 (4) | 9 (4) | 22 (4) | |
| Skin (C43-C44) | 28 (4) | 4 (2) | 24 (5) | |
| Breast (C50) | 38 (5) | 14 (6) | 24 (5) | |
| Cervix uteri (C53) | 9 (1) | 1 (<1) | 8 (2) | |
| Corpus uteri (C54) | 13 (2) | 4 (2) | 9 (2) | |
| Prostate (C61) | 22 (3) | 12 (6) | 10 (2) | |
| Kidney (C64-C65) | 15 (2) | 10 (5) | 5 (1) | |
| Bladder (C67) | 19 (3) | 7 (3) | 12 (2) | |
| Central nervous system (C71-72) | 16 (2) | 2 (1) | 14 (3) | |
| Thyroid (C73) | 28 (4) | 6 (3) | 22 (4) | |
| Other‡ | 41 (6) | 15 (7) | 26 (5) | |
| Year of diagnosis of solid cancer | .12 | |||
| 1993-1999 | 18 (3) | 9 (4) | 9 (2) | |
| 2000-2004 | 88 (12) | 31 (14) | 57 (11) | |
| 2005-2009 | 203 (28) | 52 (24) | 151 (30) | |
| 2010-2015 | 404 (57) | 125 (58) | 279 (56) | |
| Primary disease | <.001 | |||
| Acute myeloid leukemia | 171 (24) | 20 (9) | 151 (30) | |
| Acute lymphoblastic leukemia | 101 (14) | 7 (3) | 94 (19) | |
| Myelodysplastic syndrome/myeloproliferative neoplasms | 77 (11) | 1 (<1) | 76 (15) | |
| Chronic myelogenous leukemia | 60 (8) | 0 (0) | 60 (12) | |
| Malignant lymphoma | 227 (32) | 160 (74) | 67 (14) | |
| Plasma cell neoplasms | 34 (5) | 29 (13) | 5 (1) | |
| Adult T-cell leukemia/lymphoma | 20 (3) | 0 (0) | 20 (4) | |
| Aplastic anemia | 21 (3) | 0 (0) | 21 (4) | |
| Other | 2 (<1) | 0 (0) | 2 (<1) | |
| Prior history of HCT | 27 (4) | 13 (6) | 14 (3) | .04 |
| Graft source | <.001 | |||
| Bone marrow | 352 (49) | 12 (6) | 340 (69) | |
| Mobilized blood cells | 313 (44) | 205 (94) | 108 (22) | |
| Cord blood | 48 (7) | 0 (0) | 48 (10) | |
| TBI in conditioning regimen | 324 (45) | 21 (10) | 303 (61) | <.001 |
| Donor relation | ||||
| Related | 271 (55) | |||
| Unrelated | 225 (45) | |||
| HLA matching | ||||
| Match | 299 (60) | |||
| Mismatch | 143 (29) | |||
| Unknown | 54 (11) | |||
| Conditioning intensity | ||||
| Myeloablative | 245 (49) | |||
| Reduced intensity | 146 (29) | |||
| Unknown intensity | 105 (21) | |||
| Chronic GVHD | ||||
| None | 410 (58) | |||
| Limited | 110 (15) | |||
| Extensive | 193 (27) |
ICD-10, International Classification of Diseases, 10th revision.
*
P values for autologous vs allogeneic HCT.
†
Includes soft tissue cancers defined as ICD-O3 880-892, 912, and 918-926.
‡
Nine patients had bile duct cancer, 8 cancer of unknown origin, 6 malignant peripheral nerve sheath tumor, 6 duodenum cancer, 4 ovarian cancer, 3 parotid gland cancer, 3 ureter cancer, 1 laryngeal cancer, and 1 submandibular gland cancer.